149
Participants
Start Date
August 10, 2018
Primary Completion Date
February 28, 2020
Study Completion Date
March 1, 2020
Recombinant human urokinase
Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Aspirin
Aspirin 300mg is taken orally at the beginning of thrombolysis.
rhPro-UK simulation agent
Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Aspirin simulation agent
Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
XuanWu Hospital, Capital Medical University, Beijing
Harrison International Peace Hospital, Hengshui
Tangshan Gongren Hospital, Tangshan
Baotou Central Hospital, Baotou
First Affiliated Hospital of Baotou Medical College, Baotou
Affiliated Hospital of Inner Mongolia Medical University, Hohhot
Inner Mongolia People's Hospital, Hohhot
Huai'an First People's Hospital, Huai'an
The Second People'Hospital of Huai'an, Huai'an
Zhongda Hospital Southeast University, Nanjing
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Xuzhou Central Hospital, Xuzhou
Jiangxi Pingxiang People's Hospital, Pingxiang
First Hospital of Jilin University, Changchun
Meihekou Central Hospital, Meihekou
Dalian Municipal Central Hospital, Dalian
Shenyang Military Region General Hospital, Shenyang
The First People's Hospital of Shenyang, Shenyang
Luoyang Central Hospital, Luoyang
Tasly Biopharmaceuticals Co., Ltd.
INDUSTRY